New method at the Danish Medicines Council gives Merck hope of a Danish breakthrough for its sclerosis treatment

German pharmaceutical company Merck has high hopes that a new method of evaluating treatments at the Danish Medicines Council, as well as new data, will pave the way for wider usage of sclerosis drug Mavenclad.

Enrique Álvarez Fernández became head of Merck in Denmark in June 2019. Photo: Merck/PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles